Treatment of Tardive Dyskinesia With Galantamine

• Status: Completed
• Trial end date: 2004-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Tardive dyskinesia (TD), a form of movement disorder, remains a problem for some patients who received antipsychotic medications. Increasing evidence suggests that TD may result from antipsychotic-induced dysfunction in striatal cholinergic neurons. To test whether cholinesterase inhibitors compensate for diminished cholinergic activity underlying TD, we conducted a 30-week randomized, double-blind, placebo-controlled crossover study of galantamine in 36 patients with TD.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Caroff, Stanley N., M.D.
• Collaborator: Ortho-McNeil Neurologics, Inc.
• Treatments: Galantamine

Criteria

Inclusion Criteria:

• Clinical diagnosis of tardive dyskinesia lasting at least 3 months

• Treatment with antipsychotic drugs at least for 3 months

• 18 years old or older

Exclusion Criteria:

• Significant active medical illness

• Allergy to galantamine

• Pregnancy

• Drug or alcohol dependence

• Necessary use of anticholinergics or vitamin E